Kyprolis® (carfilzomib) for Injection: 003-A1 Phase 2 Study Results*
22.9% OVERALL RESPONSE RATE (ORR) (95% CI: 18.0, 28.5)1
7.8-MONTH MEDIAN DURATION OF RESPONSE (95% CI: 5.6, 9.2)1
Most patients across all phase 2 studies (85%) did not need to discontinue therapy due to an adverse event1,2
- Adverse reactions leading to discontinuation included congestive heart failure (2%), cardiac arrest,
dyspnea, increased blood creatinine, and acute renal failure (1% each)1
*Study PX-171-003 was a single-arm, multicenter clinical trial of KYPROLIS in 266 patients with relapsed multiple myeloma who had received
at least two prior therapies (including bortezomib and thalidomide and/or lenalidomide) and whose disease had a ≤25% response to the
most recent therapy or had disease progression during or within 60 days of the most re